TY - JOUR
T1 - Prevalence of multiple sclerosis symptoms across lifespan
T2 - data from the NARCOMS Registry
AU - Fox, Robert J.
AU - Bacon, Tamar E.
AU - Chamot, Eric
AU - Salter, Amber R.
AU - Cutter, Gary R.
AU - Kalina, Jennifer T.
AU - Kister, Ilya
PY - 2015/1/1
Y1 - 2015/1/1
N2 - The North American Research Committee on Multiple Sclerosis is a voluntary patient registry with more than 38,000 registrants as of 2015. In a recent collaborative project, longitudinal data on patient-perceived impairment in 11 domains commonly affected by multiple sclerosis were examined and tabulated as a function of disease duration. The patterns of disability accumulation differed by domain. Certain symptoms (sensory, fatigue) were particularly prevalent early in the disease. Other symptoms (mobility, hand function, fatigue, bowel/bladder dysfunction, spasticity) were progressively more common with longer disease duration. Some symptoms (vision, cognition, sensory, pain, depression) were relatively common early on in multiple sclerosis, but did not appear to be more frequent with longer disease duration. Ongoing research includes studies of the impact of disease-modifying therapy and symptomatic treatment on patient-perceived impairment over the disease course.
AB - The North American Research Committee on Multiple Sclerosis is a voluntary patient registry with more than 38,000 registrants as of 2015. In a recent collaborative project, longitudinal data on patient-perceived impairment in 11 domains commonly affected by multiple sclerosis were examined and tabulated as a function of disease duration. The patterns of disability accumulation differed by domain. Certain symptoms (sensory, fatigue) were particularly prevalent early in the disease. Other symptoms (mobility, hand function, fatigue, bowel/bladder dysfunction, spasticity) were progressively more common with longer disease duration. Some symptoms (vision, cognition, sensory, pain, depression) were relatively common early on in multiple sclerosis, but did not appear to be more frequent with longer disease duration. Ongoing research includes studies of the impact of disease-modifying therapy and symptomatic treatment on patient-perceived impairment over the disease course.
KW - NARCOMS
KW - multiple sclerosis
KW - patient registries
KW - patient-reported outcomes
KW - performance scales
UR - http://www.scopus.com/inward/record.url?scp=85050577824&partnerID=8YFLogxK
M3 - Article
C2 - 26611264
AN - SCOPUS:85050577824
SN - 1758-2032
VL - 5
SP - 3
EP - 10
JO - Neurodegenerative disease management
JF - Neurodegenerative disease management
IS - 6
ER -